01 /What it is
Ipamorelin is a synthetic pentapeptide first described in the late 1990s. It is structurally classified as a growth hormone secretagogue and is one of the more selective ghrelin receptor agonists in the research peptide category.
02 /How it works
In research models, Ipamorelin is studied as a selective agonist at the ghrelin/GHS-R1a receptor in the anterior pituitary. Its selectivity profile in research settings is associated with minimal observed cross activity at cortisol and prolactin pathways relative to older GHRPs.
03 /What researchers explore it for
Researchers have explored Ipamorelin in growth hormone axis research, in combination pairing research with GHRH analogs such as CJC-1295 (no DAC), and in receptor selectivity research.
04 /Safety and interactions
Research interactions of note include co administration with GHRH analogs and with other ghrelin receptor agonists, which is commonly studied as a synergistic pairing. Ipamorelin is for laboratory research use only and is not for human consumption. Not medical advice. Not intended to diagnose, treat, cure, or prevent any disease.
05 /Research notes
Peptide family: ghrelin receptor agonists (GHRPs). Frequently compared with GHRP-2, GHRP-6, and Hexarelin. Commonly researched alongside CJC-1295 (no DAC). Lyophilized powder; reconstitution and storage handling per laboratory protocols.
Related peptides
CJC-1295 (no DAC) · GHRP-2 · GHRP-6 · Hexarelin
